Stephan Carlson, MD
Psychiatry · Brooklyn, NYNPI 1275680068
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $157,960 of the $184,046 with a category attached, or 85.8%. 11 manufacturers reported payments, led by Johnson & Johnson at 55.5% of the total. Reporting peaked in 2019 at $47,382 and has fallen 67.1% since, to $15,568 in 2025. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $561.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$102K
- Alkermes, Inc.$71K
- E.r. Squibb & Sons, L.L.C.$10K
- Teva Pharmaceuticals USA, Inc.$382
- Otsuka America Pharmaceutical, Inc.$308
- Neurocrine Biosciences, Inc.$235
- plus $246 from 5 others
What the payments were for
- Consulting fees$7,6174%
- Speaking & faculty fees$157,96086%
- Travel & lodging$8,6405%
- Food & beverage$9,7185%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 161 | $102,219 |
| Alkermes, Inc. | 101 | $70,862 |
| E.r. Squibb & Sons, L.L.C. | 21 | $9,793 |
| Teva Pharmaceuticals USA, Inc. | 12 | $382 |
| Otsuka America Pharmaceutical, Inc. | 14 | $308 |
| Neurocrine Biosciences, Inc. | 9 | $235 |
| Bioxcel Therapeutics, Inc. | 3 | $70 |
| AbbVie | 2 | $51 |
| Lundbeck LLC | 2 | $44 |
| Janssen Scientific Affairs, LLC | 1 | $41 |
| Indivior Inc. | 2 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$277,025
- INVEGA SUSTENNA$99,288
- INVEGA TRINZA$97,152
- ARISTADA INITIO$69,156
- COBENFY$1,620
- LYBALVI$577
- INVEGA$250
- SPRAVATO$250
How this compares
$184,046 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Brooklyn
- Mark OwensBrooklyn$286K
- Nancy Abdel-WahabBrooklyn$253K
- Louis BelzieBrooklyn$161K
- Nikhil PalekarBrooklyn$115K
- Alexander PinkusovichBrooklyn$95K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.